Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies

Rheumatology (Oxford, England)

Volumn 56, Issue 1, 2017, Pages 46-57

  Schulze Koops, Hendrik ^a   Strand, Vibeke ^a   Nduaka, Chudy ^a   DeMasi, Ryan ^a   Wallenstein, Gene ^a   Kwok, Kenneth ^a   Wang, Lisy ^a  

^a PFIZER INC   (United States)

Author keywords

anaemia; disease activity; fatigue; haemoglobin; lymphocyte; neutrophil; rheumatoid arthritis; tofacitinib; vitality

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TOFACITINIB;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CELL COUNT; COMPLICATION; CYTOLOGY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALE; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CELL COUNT; CLINICAL TRIALS, PHASE III AS TOPIC; FATIGUE; FEMALE; HEMOGLOBINS; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85021853917     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew329     Document Type: Article

References (0)